Alzamend Neuro initiates Phase I/IIA trial of ALZN002 for mild to moderate Alzheimer's dementia

Alzamend Neuro, Inc.

Initiated Phase I/IIA clinical trial of immunotherapy vaccine ALZN002 for mild to moderate Alzheimer's dementia.
Primary goal: determine appropriate dose for Phase IIB trial; Phase IIB expected within 3 months of initial data.
Enrolling 20-30 subjects with mild to moderate morbidity; assesses safety, tolerability, efficacy vs placebo.
CEO states ALZN002 may limit infusions, reduce adverse reactions, and improve cognitive outcomes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.